Home›Stock Screener›Hemo Organic

Hemo Organic Share Price Today | Stock Price & Hemo Organic Share Screener

HEMORGANIC Trading & Distributors
Live Share Price BSE
₹21.88
▲ 1.04 (4.99%)
2026-09-28 00:00:00

As of September 28, 2026, the live Hemo Organic share price (BSE: HEMORGANIC) is ₹21.88, up 4.99% from the previous close, with shares trading between ₹21.86 and ₹21.88 in today's trading session, and a 52-week range of ₹8.31–₹24.42. Check HEMORGANIC yearly price range for the annual price range and momentum. Use the Hemo Organic stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Hemo Organic opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Hemo Organic Market Cap ₹6.72 Cr.
HEMORGANIC P/E Ratio (TTM) 63.24
Hemo Organic P/B Ratio -23.72
EPS (TTM) ₹0.47
Dividend Yield -
Debt to Equity -
HEMORGANIC 52 Week High ₹24.42
Hemo Organic 52 Week Low ₹8.31
Operating Margin 2.00%
Profit Margin -
HEMORGANIC Revenue (TTM) ₹3.00
EBITDA -
Net Income -
Total Assets ₹5.00
Total Equity -

Hemo Organic Share Price Chart

Track the current stock price of Hemo Organic with an interactive chart. Analyse HEMORGANIC share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Hemo Organic stock quote in one place.

The quote of ₹21.88 sits between the 52-week low of ₹8.31 and the 52-week high of ₹24.42, and the latest session moved 4.99% from the previous close.

Hemo Organic Company Profile - Fundamental Screener

Screen Hemo Organic company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for HEMORGANIC shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Commercial Services sector and the Trading & Distributors industry, and it trades under ISIN INE422G01015.

Company Details

Classification

Sector Commercial Services
Industry Trading & Distributors
Sub-Sector Trading & Distributors
Segment E

Identifiers and Leadership

ISIN INE422G01015

Hemo Organic Balance Sheet Screener

Screen HEMORGANIC balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2025, total assets were ₹5, up from ₹1 in 2024.

Item 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016

Assets

Total Assets 5 1 0 0 0 0 1 1 1 1
Current Assets 5 1 0 0 0 0 1 1 1 0
Fixed Assets 0 0 0 0 0 0 0 0 0 0

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 2 1 0 0 0 0 0 0 0 0
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 0 0 0 0 0 0 0 0 0 0
Share Capital 4 4 4 4 4 4 4 4 4 3
Reserves & Surplus -4 -4 -4 -4 -3 -3 -3 -3 -3 -3

Hemo Organic Income Statement Screener - Profit & Revenue Analysis

Screen Hemo Organic income statement and profit fundamentals. Analyze HEMORGANIC quarterly results. Hemo Organic reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For None-None, revenue was ₹3 and net profit was ₹0, equal to earnings per unit of ₹0.30, at an operating margin of 2%.

In that period expenses were ₹3, interest cost ₹0 and tax ₹0. The next period listed, 2025-March, shows revenue of ₹3 and net profit of ₹0.

Item None-None 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2016-March 2015-March

Revenue and Expenses

Revenue 3 3 0 0 0 0 0 0 0 1 0 0
Expenses 3 3 0 0 0 0 0 0 0 1 0 0

Operating Costs and Margins

EBITDA 0 0 0 0 0 0 0 0 0 0 0 0
Operating Profit % 2.00% -2.00% -1099.00% -1138.00% -912.00% -593.00% -8.00% -220.00% -170.00% -13.00% -50.00% -38.00%
Depreciation 0 0 0 0 0 0 0 0 0 0 0 0
Interest 0 0 0 0 0 0 0 0 0 0 0 0

Profit and Earnings

Profit Before Tax 0 0 0 0 0 0 0 0 0 0 -1 0
Tax 0 0 0 0 0 0 0 0 0 0 0 0
Net Profit 0 0 0 0 0 0 0 0 0 0 -1 0
EPS 0.30 0.47 -0.76 -0.16 -0.18 -0.14 -0.06 -0.35 -0.43 -0.23 -2.42 -0.31

Hemo Organic Cash Flow Screener - Liquidity Fundamentals

Screen HEMORGANIC cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2025-March, operating activities generated ₹0.

Over the same period, investing activities provided ₹0 and financing activities provided ₹0.

Item 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2016-March

Cash from Operations and Investing

Operating Activities 0 -1 0 0 0 0 0 0 0 -1
Investing Activities 0 0 0 0 0 0 0 0 0 1

Financing and Net Cash

Financing Activities 0 1 0 0 0 0 0 0 0 0
Net Cash Flow 0 0 0 0 0 0 0 0 0 0

Hemo Organic Shareholding Pattern Screener

See Hemo Organic shareholding pattern with promoter, FII, and DII holdings. Check Hemo Organic promoter holding and ownership changes for HEMORGANIC on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 16.85%, foreign institutions 0.00%, domestic institutions 0.00% and the public 71.01%, spread across 4,988 shareholders.

The shareholder count was 4,988 in 2026-Mar, compared with 5,218 in 2025-Mar.

Item 2026-Mar 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept

Promoter Holding

Promoter Holding 16.85% 16.85% 16.85% 16.85% 16.85% 16.85% 16.85% 16.85%

Institutional Investors

FII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
DII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 71.01% 71.11% 70.66% 70.64% 70.27% 73.58% 72.22% 72.05%
Other Holding 12.14% 12.04% 12.49% 12.51% 12.88% 9.57% 10.94% 11.10%
Shareholder Count 4,988 5,218 5,212 5,213 5,055 5,178 4,902 4,774

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Hemo Organic. Hemo Organic dividend yield can be compared with peers and other stocks in the market.

No dividends declared by Hemo Organic.

Hemo Organic Stock Index Membership - Nifty & Sensex

See which indices include Hemo Organic stock. Check HEMORGANIC index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Hemo Organic is not part of any tracked indices.
Only major market indices are tracked in our system.

Hemo Organic Market Events Screener - Corporate Actions

Get Hemo Organic corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Hemo Organic stock events that may affect HEMORGANIC share price, along with derivatives, futures and options activity and sector gainers.

9 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated February 13, 2026, with a record date of February 13, 2026.

It is followed by Extraordinary General Meeting dated January 7, 2026 and Quarterly Result Announcement dated November 14, 2025.

Announcement Date Record Date Event Type Information Price Impact
2026-02-13 2026-02-13 Quarterly Result Announcement NA -7.02%
2026-01-07 2026-01-07 Extraordinary General Meeting NA 11.56%
2025-11-14 2025-11-14 Quarterly Result Announcement NA 15.73%
2025-09-29 2025-09-29 Annual General Meeting NA 11.58%
2025-08-13 2025-08-13 Quarterly Result Announcement NA 2.70%
2025-05-20 2025-05-20 Quarterly Result Announcement NA 3.30%
2025-02-06 2025-02-06 Quarterly Result Announcement NA -2.82%
2024-10-28 2024-10-28 Quarterly Result Announcement NA -14.15%
2024-09-11 2024-09-11 Annual General Meeting NA 19.11%

Hemo Organic Competitors Screener - Peer Stocks Comparison

Screen HEMORGANIC competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Commercial Services sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Redington 17,281 13.37 119,162 19.69% 1,158 50.58
MMTC 9,647 36.42 263 28.63% 87 51.32
Elitecon International 5,019 15.65 551 55040.00% 70 26.20
BN Agrochem 3,204 59.66 367 5071.83% 20 74.13
MSTC 3,001 13.82 388 -25.38% 407 47.01
Ravindra Energy 2,308 28.48 543 107.17% 84 43.20
Vintage Coffee & Beverages 1,873 26.72 553 76.98% 72 44.55
TCC Concept 1,855 33.61 90 14.72% 42 55.53
Creative Newtech 963 13.81 2,700 49.86% 70 53.14
The Yamuna Syndicate 876 8.00 68 -16.34% 115 45.33

Hemo Organic Company Announcements - News & Reports Screener

Screen HEMORGANIC latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated April 30, 2026.

The next most recent announcements are dated April 9, 2026 and March 31, 2026.

Date Update Actions
2026-04-30 Non-Applicability Of SEBI Circular SEBI/HO/DDHS/DDHS RACPOD1/P/CIR/2023/172October19 2023 - Initial Disclosure For Large Corporate Entity For F.Y. 2026-27. -
2026-04-09 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-03-31 Announcement under Regulation 30 (LODR)-Change in Management -
2026-03-31 Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. Tuesday 31St March 2026 -
2026-03-25 Closure of Trading Window -
2026-02-26 Announcement under Regulation 30 (LODR)-Change in Registered Office Address -
2026-02-26 Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. Thursday 26Th February 2026 -
2026-02-17 Intimation Of In-Principle Approval Received For Issue Of Convertible Warrants On Preferential Basis By Hemo Organic Limited (The Company) Under Regulation 28(1) Of The SEBI (LODR) Regulations 2015 -
2026-02-14 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-02-13 Submission Of Un-Audited Financial Results Along With Limited Review Report Thereon For The Quarter And Nine Months Ended On 31St December 2025 -
2026-02-13 Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. Friday 13Th February 2026 -
2026-02-13 Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. Friday 13Th February 2026 -
2026-02-10 Board Meeting Intimation for Board Meeting Intimation For Meeting To Be Held On Friday 13Th February 2026. -
2026-01-09 Submission Of Voting Result Of Extra Ordinary General Meeting Of M/S. Hemo Organics Limited -
2026-01-09 Shareholder Meeting / Postal Ballot-Scrutinizer"s Report -
2026-01-07 Shareholder Meeting / Postal Ballot-Outcome of EGM -
2026-01-06 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2025-12-30 Closure of Trading Window -
2025-12-18 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2025-12-16 Notice Of Extra-Ordinary General Meeting (EGM) Of The Company -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹21.88, within a 52-week range of ₹8.31 to ₹24.42. The P/E ratio is 63.24 and the P/B ratio is -23.72, with earnings per unit of ₹0.47. Market capitalisation stands at ₹6.72 Cr. The company operates in the Commercial Services sector, in the Trading & Distributors industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the BSE. Key statistics were last updated on October 6, 2026. This page covers 10 balance sheet periods, 12 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.